Retrospective comparisons of adolescents/young adults treated on pediatric and adult protocols.
| Author . | Reference . | Study group . | n . | Median age, y . | CR, % . | Relapse, % . | TRM, % . | OS, % . |
|---|---|---|---|---|---|---|---|---|
| P indicates pediatric; A, adult; CR, complete remission; TRM, treatment-related mortality; EFS, event-free survival; OS, overall survival; NA, not available. | ||||||||
| Stock | 13 | CCG (P) | 197 | 16 | 90 | NA | 63 | 67 |
| CALGB (A) | 124 | 19 | 90 | NA | 34 | 46 | ||
| Boissel | 14 | FRALLE-93 (P) | 77 | 15.9 | 94 | 15 | 6 | 67 |
| LALA-94 (A) | 100 | 17.9 | 83 | 46 | 1 | 41 | ||
| deBont | 15 | DCOG (P) | 47 | 115.4 | 98 | 27 | 4 | 69 |
| HOVON 15–18(A) | 44 | 16.9 | 91 | 55 | 25 | 34 | ||
| HOVON 19–20(A) | 29 | 19.5 | 90 | 50 | 21 | 34 | ||
| Testi | 18 | AIEOP (P) | 150 | 15 | 94 | 17 | NA | NA |
| GIMEMA (A) | 95 | 16 | 89 | 45 | NA | NA | ||
| Hallböök | 16 | NOPHO-92 (P) | 36 | 15.6 | 99 | NA | NA | 74 |
| Adult ALL Grp (A) | 99 | 18.2 | 90 | 39 | ||||
| Ramanujachar | 17 | ALL-97/99 (P) | 61 | NA | 98 | 25 | 7 | 65 |
| MRCUKALLXII/ECOG2993 (A) | 67 | range 15–17 | 94 | 28 | 16 | 49 | ||
| Usvasalo | 19 | NOPHO (P) | 128 | 12.9 | 96 | 26 | 3 | 67 |
| Finnish Leukemia(A) | 97 | 18.9 | 97 | 31 | 5 | 60 | ||
| Thomas | 24 | MD Anderson (A) | 102 | 19 | 97 | NA | NA | 65 |
| Author . | Reference . | Study group . | n . | Median age, y . | CR, % . | Relapse, % . | TRM, % . | OS, % . |
|---|---|---|---|---|---|---|---|---|
| P indicates pediatric; A, adult; CR, complete remission; TRM, treatment-related mortality; EFS, event-free survival; OS, overall survival; NA, not available. | ||||||||
| Stock | 13 | CCG (P) | 197 | 16 | 90 | NA | 63 | 67 |
| CALGB (A) | 124 | 19 | 90 | NA | 34 | 46 | ||
| Boissel | 14 | FRALLE-93 (P) | 77 | 15.9 | 94 | 15 | 6 | 67 |
| LALA-94 (A) | 100 | 17.9 | 83 | 46 | 1 | 41 | ||
| deBont | 15 | DCOG (P) | 47 | 115.4 | 98 | 27 | 4 | 69 |
| HOVON 15–18(A) | 44 | 16.9 | 91 | 55 | 25 | 34 | ||
| HOVON 19–20(A) | 29 | 19.5 | 90 | 50 | 21 | 34 | ||
| Testi | 18 | AIEOP (P) | 150 | 15 | 94 | 17 | NA | NA |
| GIMEMA (A) | 95 | 16 | 89 | 45 | NA | NA | ||
| Hallböök | 16 | NOPHO-92 (P) | 36 | 15.6 | 99 | NA | NA | 74 |
| Adult ALL Grp (A) | 99 | 18.2 | 90 | 39 | ||||
| Ramanujachar | 17 | ALL-97/99 (P) | 61 | NA | 98 | 25 | 7 | 65 |
| MRCUKALLXII/ECOG2993 (A) | 67 | range 15–17 | 94 | 28 | 16 | 49 | ||
| Usvasalo | 19 | NOPHO (P) | 128 | 12.9 | 96 | 26 | 3 | 67 |
| Finnish Leukemia(A) | 97 | 18.9 | 97 | 31 | 5 | 60 | ||
| Thomas | 24 | MD Anderson (A) | 102 | 19 | 97 | NA | NA | 65 |